Don Frail, Ph.D.

Senior Advisor

Don is a Senior Advisor on the Frazier Life Sciences team with over 30 years of experience as a biologist/ pharmacologist and leader of pharmaceutical research and external science divisions.

Don joined Frazier Healthcare Partners in 2020 and brings significant experience in drug discovery and development to the Life Sciences team.

Don spent over 30 years in drug discovery research and development at Allergan, AstraZeneca, Pfizer, Pharmacia, Wyeth and Abbott. Most recently, Don was a Senior Vice President in R&D at Allergan where he led an organization responsible for research and preclinical functions, clinical pharmacology, and the scientific arm of business development, while also co-leading the governance of the pre-POC clinical development portfolio.

Don has been involved in the entry of over 25 compounds into clinical development across multiple therapeutic areas. Don has also been involved in more than 25 business development deals since 2015, including sizeable compound and company acquisitions, licensing partnerships, option deals, build to buys, and outlicenses. He created unique drug repositioning units at AstraZeneca and Pfizer, and groundbreaking partnership models for drug development with the National Institutes of Health and the Medical Research Council UK.

Don received a Ph.D. in Biochemistry from McGill University in Montreal, Quebec a B.S. in Biology and Mathematics from SUNY at Stony Brook, and completed a post-doctoral fellowship in Pharmacology and Neuroscience at the Washington University School of Medicine in St. Louis, MO. He has published over 70 peer reviewed articles and patents.

Location
Boston
Education

McGill University in Montreal, Quebec ( Ph.D.)
SUNY at Stony Brook (B.S.)

Year Joined
2020
Contact